NORD and Amgen Team Up for Learning Collaborative to Enhance Rare Disease Care
In a groundbreaking initiative, the National Organization for Rare Disorders (NORD®) has partnered with Amgen to establish a Learning Collaborative aimed at significantly improving the diagnosis and treatment of rare autoimmune diseases. The collaboration is designed to tackle the pressing issue of delayed diagnosis, a significant challenge within the healthcare system for patients suffering from these conditions.
This new effort will bring together a network of NORD's Rare Disease Centers of Excellence, focusing initially on two challenging medical conditions: IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED). Both conditions are notoriously difficult to diagnose and require coordinated care across multiple medical specialties. The pilot project, which will last for 14 months, is set to engage five to eight participating institutions that will work collaboratively to address the multifaceted diagnostic challenges and improve care pathways.
Pam Gavin, President and Chief Executive Officer of NORD, expressed enthusiasm about the collaboration, stating, "When NORD established its Rare Disease Centers of Excellence network, our vision was to aggregate expertise from leading medical institutions to tackle issues too complex for any single entity to resolve. Amgen has embraced this vision and is committed to making strides in rare disease care. By uniting the strengths of various institutions and directly involving patients and caregivers, we aim to address specific challenges while also creating frameworks that may assist other rare diseases in the future.
During the Learning Collaborative, clinical professionals from the participating centers will team up with patients, caregivers, and disease-specific advocacy groups. They will collaboratively analyze the current state of diagnostics, referrals, and care coordination, ultimately identifying gaps that cause delays in treatment. The project aims to generate tailored approaches for enhancing recognition and support for IgG4-RD and TED, while simultaneously offering broader insights into overcoming diagnostic hurdles in other rare diseases facing similar obstacles.
Kat Provencher, Director of Patient Advocacy at the IgG4ward! Foundation, underscored the significance of patient involvement in this initiative. As a caregiver for her husband who battles IgG4-RD, she conveyed the overwhelming nature of navigating these complex diseases and the importance of streamlined care pathways. "For families facing these conditions, achieving a diagnosis is only the beginning. It can often be just as challenging to manage ongoing care across various specialists. This collaboration gives patients and caregivers an opportunity to voice their experiences and assist in shaping solutions, easing the burdens on future patients," she noted.
Paul Burton, M.D., Ph.D., senior vice president and chief medical officer at Amgen, echoed these sentiments, stating, "For too long, individuals living with rare autoimmune diseases encounter a lengthy and uncertain journey to diagnosis and appropriate treatment. Patients deserve timely answers. Through our efforts in partnership with NORD and SPAARK, we are utilizing diverse insights to dismantle barriers to swift diagnosis, facilitating faster progress in care that can reach those who need it most."
Since its inception in 2021, NORD's Rare Disease Centers of Excellence network has expanded to include 49 designated centers across over 170 affiliated institutions. This network plays a crucial role in connecting specialized clinical skills and institutional assets to address the stark gaps in rare disease diagnosis and care. The establishment of the Learning Collaborative is an extension of this mission, a structured opportunity for institutions to exchange knowledge and cultivate effective solutions to shared challenges.
It is important to note that NORD will maintain independent scientific oversight throughout the collaborative. They will develop educational resources to foster evidence-based and patient-centered care without endorsing specific medications or treatments. This initiative represents a concerted effort to change the landscape of rare disease care, ensuring that all patients receive the quality of care they truly deserve.
The collaboration also ties in with the objectives of SPAARK (Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge), a partnership involving 10 advocacy and professional organizations that aims to reduce diagnosis times for rare autoimmune diseases by half by 2036. The aspirations of this partnership align seamlessly with NORD and Amgen's mission to create impactful change in the area of rare diseases.
In summary, the collaboration between NORD and Amgen signifies a significant step forward in addressing the needs of individuals affected by rare autoimmune diseases. By leveraging collective expertise and insights, this initiative has the potential to not only shorten diagnosis times for patients but also improve the quality and accessibility of care they receive, paving the way for a brighter future in rare disease management.
This new effort will bring together a network of NORD's Rare Disease Centers of Excellence, focusing initially on two challenging medical conditions: IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED). Both conditions are notoriously difficult to diagnose and require coordinated care across multiple medical specialties. The pilot project, which will last for 14 months, is set to engage five to eight participating institutions that will work collaboratively to address the multifaceted diagnostic challenges and improve care pathways.
Pam Gavin, President and Chief Executive Officer of NORD, expressed enthusiasm about the collaboration, stating, "When NORD established its Rare Disease Centers of Excellence network, our vision was to aggregate expertise from leading medical institutions to tackle issues too complex for any single entity to resolve. Amgen has embraced this vision and is committed to making strides in rare disease care. By uniting the strengths of various institutions and directly involving patients and caregivers, we aim to address specific challenges while also creating frameworks that may assist other rare diseases in the future.
During the Learning Collaborative, clinical professionals from the participating centers will team up with patients, caregivers, and disease-specific advocacy groups. They will collaboratively analyze the current state of diagnostics, referrals, and care coordination, ultimately identifying gaps that cause delays in treatment. The project aims to generate tailored approaches for enhancing recognition and support for IgG4-RD and TED, while simultaneously offering broader insights into overcoming diagnostic hurdles in other rare diseases facing similar obstacles.
Kat Provencher, Director of Patient Advocacy at the IgG4ward! Foundation, underscored the significance of patient involvement in this initiative. As a caregiver for her husband who battles IgG4-RD, she conveyed the overwhelming nature of navigating these complex diseases and the importance of streamlined care pathways. "For families facing these conditions, achieving a diagnosis is only the beginning. It can often be just as challenging to manage ongoing care across various specialists. This collaboration gives patients and caregivers an opportunity to voice their experiences and assist in shaping solutions, easing the burdens on future patients," she noted.
Paul Burton, M.D., Ph.D., senior vice president and chief medical officer at Amgen, echoed these sentiments, stating, "For too long, individuals living with rare autoimmune diseases encounter a lengthy and uncertain journey to diagnosis and appropriate treatment. Patients deserve timely answers. Through our efforts in partnership with NORD and SPAARK, we are utilizing diverse insights to dismantle barriers to swift diagnosis, facilitating faster progress in care that can reach those who need it most."
Since its inception in 2021, NORD's Rare Disease Centers of Excellence network has expanded to include 49 designated centers across over 170 affiliated institutions. This network plays a crucial role in connecting specialized clinical skills and institutional assets to address the stark gaps in rare disease diagnosis and care. The establishment of the Learning Collaborative is an extension of this mission, a structured opportunity for institutions to exchange knowledge and cultivate effective solutions to shared challenges.
It is important to note that NORD will maintain independent scientific oversight throughout the collaborative. They will develop educational resources to foster evidence-based and patient-centered care without endorsing specific medications or treatments. This initiative represents a concerted effort to change the landscape of rare disease care, ensuring that all patients receive the quality of care they truly deserve.
The collaboration also ties in with the objectives of SPAARK (Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge), a partnership involving 10 advocacy and professional organizations that aims to reduce diagnosis times for rare autoimmune diseases by half by 2036. The aspirations of this partnership align seamlessly with NORD and Amgen's mission to create impactful change in the area of rare diseases.
In summary, the collaboration between NORD and Amgen signifies a significant step forward in addressing the needs of individuals affected by rare autoimmune diseases. By leveraging collective expertise and insights, this initiative has the potential to not only shorten diagnosis times for patients but also improve the quality and accessibility of care they receive, paving the way for a brighter future in rare disease management.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.